152 related articles for article (PubMed ID: 20977315)
21. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.
Maruyama H; Hirayama K; Nagai M; Ebihara I; Shimohata H; Kobayashi M
Clin Rheumatol; 2016 Oct; 35(10):2469-76. PubMed ID: 27251675
[TBL] [Abstract][Full Text] [Related]
22. Decoy receptor 3 is a prognostic factor in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Wagener N; Funke B; Tagscherer KE; Haferkamp A; Hohenfellner M; Kim S; Autschbach F; Schirmacher P; Roth W
Neoplasia; 2008 Oct; 10(10):1049-56. PubMed ID: 18813347
[TBL] [Abstract][Full Text] [Related]
23. DcR3 promotes hepatoma cell migration by downregulating E-cadherin expression.
Zhang H; Chen X; Li D; Cui L; Li X; Ye X; Wan X
Oncol Rep; 2017 Jul; 38(1):377-383. PubMed ID: 28560426
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas.
Zhou J; Song SD; Li DC; Zhou J; Zhu DM; Zheng SY
Asian Pac J Cancer Prev; 2012; 13(2):719-24. PubMed ID: 22524850
[TBL] [Abstract][Full Text] [Related]
25. Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis.
Aiba Y; Harada K; Komori A; Ito M; Shimoda S; Nakamura H; Nagaoka S; Abiru S; Migita K; Ishibashi H; Nakanuma Y; Nishida N; Kawashima M; Tokunaga K; Yatsuhashi H; Nakamura M
Liver Int; 2014 May; 34(5):679-88. PubMed ID: 24016146
[TBL] [Abstract][Full Text] [Related]
26. Quantification and detection of DcR3, a decoy receptor in TNFR family.
Chen J; Zhang L; Kim S
J Immunol Methods; 2004 Feb; 285(1):63-70. PubMed ID: 14871535
[TBL] [Abstract][Full Text] [Related]
27. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis.
Bamias G; Kaltsa G; Siakavellas SI; Papaxoinis K; Zampeli E; Michopoulos S; Zouboulis-Vafiadis I; Ladas SD
Clin Immunol; 2010 Nov; 137(2):242-9. PubMed ID: 20675196
[TBL] [Abstract][Full Text] [Related]
28. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.
Bamias G; Siakavellas SI; Stamatelopoulos KS; Chryssochoou E; Papamichael C; Sfikakis PP
Clin Immunol; 2008 Nov; 129(2):249-55. PubMed ID: 18757243
[TBL] [Abstract][Full Text] [Related]
29. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.
Zong L; Chen P; Wang DX
World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
31. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome.
Liu J; Zhao Z; Zou Y; Zhang M; Zhou Y; Li Y; Pang Z; Jin W
Clin Rheumatol; 2015 May; 34(5):879-85. PubMed ID: 25564309
[TBL] [Abstract][Full Text] [Related]
32. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters.
Liang QL; Wang BR; Li GH
J Zhejiang Univ Sci B; 2009 Sep; 10(9):675-82. PubMed ID: 19735100
[TBL] [Abstract][Full Text] [Related]
33. Serum decoy receptor 3, a potential new biomarker for sepsis.
Hou YQ; Xu P; Zhang M; Han D; Peng L; Liang DY; Yang S; Zhang Z; Hong J; Lou XL; Zhang L; Kim S
Clin Chim Acta; 2012 Apr; 413(7-8):744-8. PubMed ID: 22280900
[TBL] [Abstract][Full Text] [Related]
34. Increased circulating levels of tumor necrosis factor-like cytokine 1A and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery.
Li XY; Hou HT; Chen HX; Wang ZQ; He GW
J Int Med Res; 2018 Dec; 46(12):5167-5175. PubMed ID: 30213220
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum levels of decoy receptor 3 are associated with disease severity in patients with hemorrhagic fever with renal syndrome.
Dong Y; Shi D; Li M; Dai P; Wang X; Xie M
Intern Emerg Med; 2015 Aug; 10(5):567-73. PubMed ID: 25647584
[TBL] [Abstract][Full Text] [Related]
36. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.
Lee CS; Hu CY; Tsai HF; Wu CS; Hsieh SL; Liu LC; Hsu PN
Clin Exp Immunol; 2008 Mar; 151(3):383-90. PubMed ID: 18190609
[TBL] [Abstract][Full Text] [Related]
38. [Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma].
Zhao J; Hu J; Cai J
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):389-92. PubMed ID: 11810769
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.
Wu Y; Han B; Sheng H; Lin M; Moore PA; Zhang J; Wu J
Int J Cancer; 2003 Jul; 105(5):724-32. PubMed ID: 12740925
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
